Combogesic

Phase 3Small molecule

AAFT Pharmaceuticals, Ltd.

Combogesic is one of 3 small molecule programs targeting Postoperative Pain, Acute. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postoperative Pain, AcuteNot yet recruiting

Postoperative Pain, AcutePhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Postoperative Pain, Acute

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Tylenol

KKenvue Brands

Phase 3

1 3

Combogesic

AAFT Pharmaceuticals, Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Postoperative Pain, Acute

NCT07225140

Clinical

Trials by Indication[1]

Postoperative Pain, Acute1 trial

A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

Not yet recruiting·AAFT Pharmaceuticals, Ltd.·Phase 3·NCT07225140·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combogesic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combogesic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combogesic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AFT Pharmaceuticals, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAFT Pharmaceuticals, Ltd.

Combogesic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Postoperative Pain, Acute1 trial

References

Drug Info

Quick Facts

Related News